Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 6Recruiting 2Withdrawn 1Terminated 1Not yet recruiting 1No longer available 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2

Conditions

Hodgkin Disease 8Mycosis Fungoides 3Lymphoma, T-Cell, Peripheral 3Recurrence 2Lymphoma, T-Cell, Cutaneous 2Sezary Syndrome 1Mesothelioma, Malignant 1Lymphomatoid Papulosis 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Large Granular Lymphocytic 1

Interventions

mogamulizumab 6Cyclophosphamide 5ruxolitinib 3pembrolizumab 3Immunoglobulin G 3Disulfides 3Biopsy 3fludarabine 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Brentuximab Vedotin 2Blood Specimen Collection 2tofacitinib 1sodium-iodide symporter 1hypericin 1fludarabine phosphate 1cemiplimab 1X-Rays 1Vincristine 1Urine Specimen Collection 1Prednisone 1Positron-Emission Tomography 1Photopheresis 1Photons 1Nivolumab 1Mycophenolic Acid 1Methoxsalen 1Mesna 1Melphalan 1MAC-ST-001 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, T-Cell, Cutaneous × Brentuximab Vedotin × Clear all
NCT05414500 2026-04-09

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

University of Alabama at Birmingham

Phase 1 Recruiting
10 enrolled
DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT05313243 2025-03-20

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

Yale University

Phase 2 Recruiting
32 enrolled
DermatologicLymphoid

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡